Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C, Marini B, Baldaccini D, Badalamenti M, Navarria P, Bellu L, Franceschini D, Comito T, Clerici E, Teriaca MA, Massaro M, Di Cristina L, Lo Faro L, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. J Cancer Res Clin Oncol. 2023 Jul;149(8):4411-4417. doi: 10.1007/s00432-022-04352-z. Epub 2022 Sep 15. J Cancer Res Clin Oncol. 2023. PMID: 36109401
Risk-group Classification by Recursive Partitioning Analysis of Patients Affected by Oligometastatic Renal Cancer Treated with Stereotactic Radiotherapy.
Franzese C, Navarria P, Bellu L, Marzo MA, Clerici E, Badalamenti M, Baldaccini D, Franceschini D, Comito T, Teriaca A, D'agostino G, Reggiori G, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Clin Oncol (R Coll Radiol). 2022 Jun;34(6):379-385. doi: 10.1016/j.clon.2021.12.021. Epub 2022 Jan 10. Clin Oncol (R Coll Radiol). 2022. PMID: 35027286
Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy.
Loi M, Comito T, Franzese C, Desideri I, Dominici L, Lo Faro L, Clerici E, Franceschini D, Baldaccini D, Badalamenti M, Reggiori G, Lobefalo F, Scorsetti M. Loi M, et al. Among authors: badalamenti m. J Geriatr Oncol. 2021 Sep;12(7):1100-1103. doi: 10.1016/j.jgo.2021.01.001. Epub 2021 Jan 16. J Geriatr Oncol. 2021. PMID: 33461945
Oligoprogressive castration-resistant prostate cancer treated with metastases-directed stereotactic body radiation therapy: predictive factors for patients' selection.
Franzese C, Perrino M, Marzo MA, Badalamenti M, Baldaccini D, D'Agostino G, Marini B, De Vincenzo F, Zucali PA, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Clin Exp Metastasis. 2022 Jun;39(3):449-457. doi: 10.1007/s10585-022-10158-7. Epub 2022 Feb 21. Clin Exp Metastasis. 2022. PMID: 35190933
Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity.
Franzese C, Badalamenti M, Di Brina L, D'Agostino G, Franceschini D, Comito T, Clerici E, Navarria P, Reggiori G, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Strahlenther Onkol. 2020 Jul;196(7):608-616. doi: 10.1007/s00066-020-01619-7. Epub 2020 Apr 17. Strahlenther Onkol. 2020. PMID: 32303782
Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases.
Franzese C, Comito T, Tripoli A, Franceschini D, Clerici E, Navarria P, Badalamenti M, D'agostino G, Loi M, Mancosu P, Reggiori G, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Clin Exp Metastasis. 2020 Oct;37(5):565-573. doi: 10.1007/s10585-020-10047-x. Epub 2020 Jun 15. Clin Exp Metastasis. 2020. PMID: 32556682 Clinical Trial.
Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?
Franzese C, Badalamenti M, Comito T, Franceschini D, Clerici E, Navarria P, Loi M, D'agostino G, Baldaccini D, Chiola I, Reggiori G, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: badalamenti m. Radiother Oncol. 2020 Sep;150:184-190. doi: 10.1016/j.radonc.2020.06.029. Epub 2020 Jun 25. Radiother Oncol. 2020. PMID: 32593644
37 results